| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Neurodegenerative processes and cellular stress responses; specific molecular targets are not extensively characterized.
|
|---|---|
| ln Vitro |
Alirinetide (GM604) inhibits the death of SH-SY5Y cells 0.1–10 mg/mL for 24 hours [1]. In SH-SY5Y cells, alidinetide (48 h) primarily inhibits genes linked to Parkinson's disease, which are primarily associated with respiratory chain and mitochondrial protein complexes [1].
GM-608 (Alirinetide, GM604) is an oligopeptide containing 6 amino acids. It penetrates the blood-brain barrier (BBB) and may be utilized in the research and study of a variety of neurodegenerative diseases. The compound has been investigated for the treatment of amyotrophic lateral sclerosis (ALS) and ischemic stroke. Specific IC50 or EC50 values for target engagement are not extensively detailed in publicly available literature. The compound is designed to interact with specific molecular targets involved in neurodegenerative processes and cellular stress responses. |
| ln Vivo |
In a 6-OHDA mouse model, incadrinetide (GM604) (0–20 mg/kg; intravenously; twice daily for 5 days) improves histological, biochemical, and behavioral features [1].
In vivo efficacy of GM-608 has been studied in animal models of amyotrophic lateral sclerosis (ALS) and ischemic stroke. As a neuroprotective agent, it has been shown to reduce neuronal damage and improve functional outcomes in these models. The compound's ability to penetrate the BBB is a key feature for its efficacy in CNS disorders. Specific dosing regimens and detailed efficacy data are available in the primary literature but not extensively detailed in public search results. |
| Enzyme Assay |
GM-608 is a synthetic peptide. Its biological activity is assessed using in vitro cell-based assays in neuronal cell cultures. Cells are treated with GM-608 at various concentrations (typically 0.001-100 µM) and subjected to stress conditions (e.g., oxidative stress, excitotoxicity). Neuroprotection is assessed by measuring cell viability, neuronal survival, and apoptotic markers. Anti-inflammatory effects are assessed by measuring cytokine production. BBB penetration is assessed using in vitro BBB models or in vivo studies.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SH-SY5Y Cell Tested Concentrations: 0.1, 1 or 10 mg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Result in dose-dependent rescue of cell survival, with complete restoration of cell viability at the highest dose (10 mg /ml). Cellular activity is evaluated in neuronal cell cultures (e.g., primary neurons, neuroblastoma cell lines). Cells are treated with GM-608 at various concentrations (typically 0.001-100 µM) for appropriate time periods. Cell viability is measured by MTT or calcein-AM staining. Apoptosis is measured by caspase-3/7 activation or Annexin V staining. Oxidative stress is measured by assessing ROS levels. Inflammatory cytokine production is measured by ELISA. Neurite outgrowth may be assessed in neuronal differentiation models. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mouse, 6-hydroxydopamine (6-OHDA) mouse model [1]
Doses: 0, 1, 5, 10 or 20 mg/kg Route of Administration: intravenous (iv) (iv)injection, twice (two times) daily, continuous 5-day Experimental Results: Almost complete abrogation of the highest dose of 6-OHDA improved motor performance, increased the number of TH-positive neurons in the substantia nigra, and increased dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid in the brain (HVA) level. In vivo efficacy is studied in animal models of amyotrophic lateral sclerosis (ALS) (e.g., SOD1-G93A transgenic mice) and ischemic stroke (e.g., middle cerebral artery occlusion model). GM-608 is administered via various routes (intravenous, intraperitoneal) at doses determined from pharmacokinetic and tolerability studies. Neurological function is assessed using behavioral tests (e.g., rotarod, grip strength, open field). Infarct size is measured in stroke models. Motor neuron survival is assessed in ALS models. Inflammatory markers are measured in brain tissue. |
| ADME/Pharmacokinetics |
GM-608 (Alirinetide, GM604) has a molecular formula of C36H54N12O9 and a molecular weight of 798.89 g/mol. CAS Number: 725715-18-4. Appearance: Typically exists as solid at room temperature. Synonyms: GM-603; GM-602; GM-604. The compound is an oligopeptide. Storage: store at -20°C for long-term stability. It is soluble in DMSO and water.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for GM-608 are not extensively published. As a research peptide, it should be handled with standard laboratory safety precautions. The compound is for research use only and not for human therapeutic applications without appropriate regulatory approval. Standard laboratory safety practices should be followed, including the use of personal protective equipment and adequate ventilation.
|
| References | |
| Additional Infomation |
GM-608 (Alirinetide, GM604) is a research tool compound for studying neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and ischemic stroke. It is not approved for clinical use. The compound is an oligopeptide that penetrates the blood-brain barrier (BBB) and may be utilized in the research and study of a variety of neurodegenerative diseases. GM-608 is designed to interact with specific molecular targets involved in neurodegenerative processes and cellular stress responses. Its neuroprotective and anti-inflammatory properties make it a valuable tool for understanding the mechanisms of neurodegeneration and for developing new therapeutic strategies for CNS disorders.
|
| Molecular Formula |
C36H54N12O9
|
|---|---|
| Molecular Weight |
798.889
|
| Exact Mass |
798.41
|
| CAS # |
725715-18-4
|
| PubChem CID |
9875671
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-4.9
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
57
|
| Complexity |
1380
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N
|
| InChi Key |
WVPOPWDCSFQEBI-HJJAOGADSA-N
|
| InChi Code |
InChI=1S/C36H54N12O9/c1-20(29(51)46-26(34(56)57)10-6-16-43-36(40)41)44-32(54)27(18-22-11-13-23(50)14-12-22)47-31(53)25(9-5-15-42-35(38)39)45-33(55)28(19-49)48-30(52)24(37)17-21-7-3-2-4-8-21/h2-4,7-8,11-14,20,24-28,49-50H,5-6,9-10,15-19,37H2,1H3,(H,44,54)(H,45,55)(H,46,51)(H,47,53)(H,48,52)(H,56,57)(H4,38,39,42)(H4,40,41,43)/t20-,24-,25-,26-,27-,28-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
|
| Synonyms |
GM-603; GM-602; GM-604
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~125.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2517 mL | 6.2587 mL | 12.5174 mL | |
| 5 mM | 0.2503 mL | 1.2517 mL | 2.5035 mL | |
| 10 mM | 0.1252 mL | 0.6259 mL | 1.2517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
